Anthropic released Claude Science on June 30, 2026—a standalone AI workbench designed for researchers in computational biology, drug discovery, and life sciences. The platform unifies over 60 scientific databases and tools (UniProt, PDB, Ensembl, Reactome, ClinVar, ChEMBL, GEO, plus journals and preprint servers) into a single environment, eliminating the need to navigate fragmented schemas and query languages individually.
Claude Science features a primary agent that coordinates specialist agents across genomics, single-cell analysis, proteomics, structural biology, and cheminformatics domains. Users run Claude's existing models (including Opus 4.8) without special access or gating, and can access compute ranging from local machines to HPC clusters and on-demand GPUs. The platform natively integrates NVIDIA's BioNeMo Agent Toolkit for life sciences models (Evo 2, Boltz-2, OpenFold3) and produces auditable artifacts with reproducible provenance. Anthropic is backing up to 50 research projects with up to $30,000 in credits each; applications close July 15.
For biotech builders and research operations, Claude Science signals Anthropic's intent to own the working layer for life sciences—similar to how Claude Code captured software engineering. Early researchers report 10x acceleration on drug design tasks with Claude Fable 5. This directly competes with OpenAI's GPT-Rosalind (released April 2026) and Google DeepMind's life sciences platforms, escalating the race for life-sciences-specific AI infrastructure.